Skip to content

Study · Non-randomized trial · n = 19 · 1990

14 results

Therapeutic efficacy of the somatostatin analog SMS 201-995 (octreotide) in acromegaly. Effects of dose and frequency and long-term safety.

Ho KY, Weissberger AJ, Marbach P, Lazarus L

Annals of internal medicine1 Feb 1990Cited by 81 (Europe PMC)

PMID2404445 (opens in a new tab)DOI10.7326/0003-4819-112-3-173 (opens in a new tab)PepBankPUB-02404445
Publisher pagePubMedAsk about this study
Jump to 14 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study14

14 results from studies that gave the peptide. 14 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In acromegaly, octreotide 100 micrograms twice or thrice daily reduced mean 12-hour GH (P less than 0.01).

    In plain wordsIn acromegaly, octreotide lowered average growth hormone compared with pretreatment.

    Peptide
    Octreotide
    Outcome
    DecreaseMean 12-hour GH
    Study

    n = 19

    Comparator
    Pretreatment
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    100 micrograms twice or thrice daily · 6 to 12 weeks per stageAs given in this study (human).

    Source sentences

    Summary
    Octreotide, 100 micrograms administered twice or thrice daily, significantly reduced mean 12-hour and nadir GH (P less than 0.01), IGF-1 (P less than 0.05), and hand volume (P less than 0.05).
    2 context sentences
    Summary · context
    Nonrandomized, controlled trial.
    Summary · context
    Sequential sample of 19 patients with active acromegaly.
  2. 02HumanNon-randomized trialEfficacy outcome

    In acromegaly, octreotide 100 micrograms twice or thrice daily reduced nadir GH (P less than 0.01).

    In plain wordsIn acromegaly, octreotide lowered the lowest growth hormone level compared with pretreatment.

    Peptide
    Octreotide
    Outcome
    DecreaseNadir GH
    Study

    n = 19

    Comparator
    Pretreatment
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    100 micrograms twice or thrice daily · 6 to 12 weeks per stageAs given in this study (human).

    Source sentences

    Summary
    Octreotide, 100 micrograms administered twice or thrice daily, significantly reduced mean 12-hour and nadir GH (P less than 0.01), IGF-1 (P less than 0.05), and hand volume (P less than 0.05).
    2 context sentences
    Summary · context
    Nonrandomized, controlled trial.
    Summary · context
    Sequential sample of 19 patients with active acromegaly.
  3. 03HumanNon-randomized trialEfficacy outcome

    In acromegaly, octreotide 100 micrograms twice or thrice daily reduced IGF-1 (P less than 0.05).

    In plain wordsIn acromegaly, octreotide lowered IGF-1 compared with pretreatment.

    Peptide
    Octreotide
    Outcome
    DecreaseIGF-1
    Study

    n = 19

    Comparator
    Pretreatment
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    100 micrograms twice or thrice daily · 6 to 12 weeks per stageAs given in this study (human).

    Source sentences

    Summary
    Octreotide, 100 micrograms administered twice or thrice daily, significantly reduced mean 12-hour and nadir GH (P less than 0.01), IGF-1 (P less than 0.05), and hand volume (P less than 0.05).
    2 context sentences
    Summary · context
    Nonrandomized, controlled trial.
    Summary · context
    Sequential sample of 19 patients with active acromegaly.
  4. 04HumanNon-randomized trialEfficacy outcome

    In acromegaly, octreotide 100 micrograms twice or thrice daily reduced hand volume (P less than 0.05).

    In plain wordsIn acromegaly, octreotide reduced hand volume compared with pretreatment.

    Peptide
    Octreotide
    Outcome
    DecreaseHand volume
    Study

    n = 19

    Comparator
    Pretreatment
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    100 micrograms twice or thrice daily · 6 to 12 weeks per stageAs given in this study (human).

    Source sentences

    Summary
    Octreotide, 100 micrograms administered twice or thrice daily, significantly reduced mean 12-hour and nadir GH (P less than 0.01), IGF-1 (P less than 0.05), and hand volume (P less than 0.05).
    2 context sentences
    Summary · context
    Nonrandomized, controlled trial.
    Summary · context
    Sequential sample of 19 patients with active acromegaly.
  5. 05HumanNon-randomized trialEfficacy outcome

    In acromegaly, increasing octreotide to 500 micrograms did not further reduce mean 12-hour GH in either group.

    In plain wordsIn acromegaly, higher octreotide doses did not further lower average growth hormone.

    Peptide
    Octreotide
    Outcome
    No significant changeMean 12-hour GH after dose increment
    Study

    n = 19

    Comparator
    Lower octreotide doses
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Increment to 500 micrograms · 6 to 12 weeks per stageAs given in this study (human).

    Source sentences

    Summary
    Dose increment to 500 micrograms in both groups did not further reduce mean 12-hour GH, nadir GH, or hand volume.
    2 context sentences
    Summary · context
    Nonrandomized, controlled trial.
    Summary · context
    Sequential sample of 19 patients with active acromegaly.
  6. 06HumanNon-randomized trialEfficacy outcome

    In acromegaly, increasing octreotide to 500 micrograms did not further reduce nadir GH in either group.

    In plain wordsIn acromegaly, higher octreotide doses did not further lower the lowest growth hormone level.

    Peptide
    Octreotide
    Outcome
    No significant changeNadir GH after dose increment
    Study

    n = 19

    Comparator
    Lower octreotide doses
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Increment to 500 micrograms · 6 to 12 weeks per stageAs given in this study (human).

    Source sentences

    Summary
    Dose increment to 500 micrograms in both groups did not further reduce mean 12-hour GH, nadir GH, or hand volume.
    2 context sentences
    Summary · context
    Nonrandomized, controlled trial.
    Summary · context
    Sequential sample of 19 patients with active acromegaly.
  7. 07HumanNon-randomized trialEfficacy outcome

    In acromegaly, increasing octreotide to 500 micrograms did not further reduce hand volume in either group.

    In plain wordsIn acromegaly, higher octreotide doses did not further reduce hand volume.

    Peptide
    Octreotide
    Outcome
    No significant changeHand volume after dose increment
    Study

    n = 19

    Comparator
    Lower octreotide doses
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Increment to 500 micrograms · 6 to 12 weeks per stageAs given in this study (human).

    Source sentences

    Summary
    Dose increment to 500 micrograms in both groups did not further reduce mean 12-hour GH, nadir GH, or hand volume.
    2 context sentences
    Summary · context
    Nonrandomized, controlled trial.
    Summary · context
    Sequential sample of 19 patients with active acromegaly.
  8. 08HumanNon-randomized trialEfficacy outcome

    In acromegaly, normalization of mean 12-hour GH and IGF-1 occurred in 8 of 19 patients during octreotide therapy.

    In plain wordsIn acromegaly, growth hormone and IGF-1 normalized in 8 of 19 octreotide-treated patients.

    Peptide
    Octreotide
    Outcome
    Not applicableNormalization of mean 12-hour GH and IGF-1
    Study

    n = 19

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated

    Measurements

    Patients with normalized mean 12-hour GH and IGF-1
    8 patients
    of 19 patients with active acromegaly

    Source sentences

    Summary
    Normalization of mean 12-hour GH and IGF-1 occurred in 8 of 19 patients; 7 of the 8 patients had pretherapy mean 12-hour GH below 20 mIU/L.
    2 context sentences
    Summary · context
    Nonrandomized, controlled trial.
    Summary · context
    Sequential sample of 19 patients with active acromegaly.
  9. 09HumanNon-randomized trialSafety outcome

    In acromegaly, gallstones were present in 9 of 18 patients after octreotide therapy.

    In plain wordsIn acromegaly, 9 of 18 patients had gallstones after octreotide therapy.

    Peptide
    Octreotide
    Outcome
    Not applicableGallstones after therapy
    Study

    n = 18

    Outcome group
    Adverse events · Gastrointestinal
    Studied dose
    Dose not stated

    Measurements

    Patients with gallstones after therapy
    9 patients
    of 18 patients after octreotide therapy

    Source sentences

    Summary
    Gallstones were present in 9 of 18 patients after therapy.
    2 context sentences
    Summary · context
    Nonrandomized, controlled trial.
    Summary · context
    Sequential sample of 19 patients with active acromegaly.
  10. 10HumanNon-randomized trialEfficacy outcome

    In acromegaly, switching octreotide from 500 micrograms twice daily to 333 micrograms thrice daily reduced mean 12-hour GH (P less than 0.05).

    In plain wordsIn acromegaly, octreotide three times daily lowered average growth hormone more than twice daily at the same daily dose.

    Peptide
    Octreotide
    Outcome
    DecreaseMean 12-hour GH after schedule switch
    Study

    n = 8

    Comparator
    500 micrograms twice daily
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    333 micrograms three times daily · 6 to 12 weeks per stageAs given in this study (human).

    Source sentences

    Summary
    Switching from 500 micrograms twice daily to 333 micrograms thrice daily resulted in significant (P less than 0.05) reduction of mean 12-hour GH, IGF-1, and hand volume.
    3 context sentences
    Summary · context
    Eight patients (group 1) were treated with 100, 250, and 500 micrograms twice daily of octreotide, then switched to 333 micrograms three times daily, whereas 11 patients (group 2) were treated with 100, 200, 300, and 500 micrograms three times daily.
    Summary · context
    Nonrandomized, controlled trial.
    Summary · context
    Sequential sample of 19 patients with active acromegaly.
  11. 11HumanNon-randomized trialEfficacy outcome

    In acromegaly, switching octreotide from 500 micrograms twice daily to 333 micrograms thrice daily reduced IGF-1 (P less than 0.05).

    In plain wordsIn acromegaly, octreotide three times daily lowered IGF-1 more than twice daily at the same daily dose.

    Peptide
    Octreotide
    Outcome
    DecreaseIGF-1 after schedule switch
    Study

    n = 8

    Comparator
    500 micrograms twice daily
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    333 micrograms three times daily · 6 to 12 weeks per stageAs given in this study (human).

    Source sentences

    Summary
    Switching from 500 micrograms twice daily to 333 micrograms thrice daily resulted in significant (P less than 0.05) reduction of mean 12-hour GH, IGF-1, and hand volume.
    3 context sentences
    Summary · context
    Eight patients (group 1) were treated with 100, 250, and 500 micrograms twice daily of octreotide, then switched to 333 micrograms three times daily, whereas 11 patients (group 2) were treated with 100, 200, 300, and 500 micrograms three times daily.
    Summary · context
    Nonrandomized, controlled trial.
    Summary · context
    Sequential sample of 19 patients with active acromegaly.
  12. 12HumanNon-randomized trialEfficacy outcome

    In acromegaly, switching octreotide from 500 micrograms twice daily to 333 micrograms thrice daily reduced hand volume (P less than 0.05).

    In plain wordsIn acromegaly, octreotide three times daily reduced hand volume more than twice daily at the same daily dose.

    Peptide
    Octreotide
    Outcome
    DecreaseHand volume after schedule switch
    Study

    n = 8

    Comparator
    500 micrograms twice daily
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    333 micrograms three times daily · 6 to 12 weeks per stageAs given in this study (human).

    Source sentences

    Summary
    Switching from 500 micrograms twice daily to 333 micrograms thrice daily resulted in significant (P less than 0.05) reduction of mean 12-hour GH, IGF-1, and hand volume.
    3 context sentences
    Summary · context
    Eight patients (group 1) were treated with 100, 250, and 500 micrograms twice daily of octreotide, then switched to 333 micrograms three times daily, whereas 11 patients (group 2) were treated with 100, 200, 300, and 500 micrograms three times daily.
    Summary · context
    Nonrandomized, controlled trial.
    Summary · context
    Sequential sample of 19 patients with active acromegaly.
  13. 13HumanObservational studyEfficacy outcome

    Among octreotide-treated acromegaly patients with normalized GH and IGF-1, 7 of 8 had pretherapy mean 12-hour GH below 20 mIU/L.

    In plain wordsAmong octreotide-treated biochemical responders, 7 of 8 had pretreatment growth hormone below 20 mIU/L.

    Peptide
    Octreotide
    Outcome
    Not applicablePretreatment GH among biochemical responders
    Study

    n = 8

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated

    Measurements

    Responders with pretherapy mean 12-hour GH below 20 mIU/L
    7 patients
    of the 8 patients with normalized GH and IGF-1
    Pretherapy mean 12-hour GH threshold
    < 20 mIU/L
    pretherapy cutoff

    Source sentences

    Summary
    Normalization of mean 12-hour GH and IGF-1 occurred in 8 of 19 patients; 7 of the 8 patients had pretherapy mean 12-hour GH below 20 mIU/L.
    2 context sentences
    Summary · context
    Nonrandomized, controlled trial.
    Summary · context
    Sequential sample of 19 patients with active acromegaly.
  14. 14HumanObservational studyEfficacy outcome

    In octreotide-treated acromegaly, pretherapy mean glucose negatively predicted glucose change during therapy (r = -0.89).

    In plain wordsIn octreotide-treated acromegaly, higher pretreatment blood glucose was linked to a lower change in blood glucose during therapy (r = -0.89).

    Peptide
    Octreotide
    Outcome
    Not applicableBaseline glucose and glucose change correlation
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Correlation (r) of pretherapy mean blood glucose with change in mean blood glucose
    −0.89 r
    octreotide therapy in acromegaly

    Source sentences

    Summary
    The pretherapy mean blood glucose was a significant negative predictor (r = -0.89) of the change in mean blood glucose during therapy.
    2 context sentences
    Summary · context
    Nonrandomized, controlled trial.
    Summary · context
    Sequential sample of 19 patients with active acromegaly.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.